(S)-6-[(5-Methyl-isoxazole-3-carbonyl)-amino]-5-oxo-1,2,3,5-tetrahydro-indolizine-3-carboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-6-[(5-Methyl-isoxazole-3-carbonyl)-amino]-5-oxo-1,2,3,5-tetrahydro-indolizine-3-carboxylic acid
• 英文别名: (3S)-6-[(5-methyl-1,2-oxazole-3-carbonyl)amino]-5-oxo-2,3-dihydro-1H-indolizine-3-carboxylic acid
• 化学式: C₁₄H₁₃N₃O₅
• 分子量: 303.274
• InChiKey: UAXKLSPSRSKPJE-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (S)-6-[(5-Methyl-isoxazole-3-carbonyl)-amino]-5-oxo-1,2,3,5-tetrahydro-indolizine-3-carboxylic acid 、 ethyl (S,E)-4-amino-5-((S)-2-oxopyrrolidin-3-yl)pent-2-enoate hydrochloride 在 N-甲基吗啉 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 生成 (E)-(S)-4-({(S)-6-[(5-Methyl-isoxazole-3-carbonyl)-amino]-5-oxo-1,2,3,5-tetrahydro-indolizine-3-carbonyl}-amino)-5-((S)-2-oxo-pyrrolidin-3-yl)-pent-2-enoic acid ethyl ester
  参考文献：
  名称：

  Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. Part 7: Structure–Activity Studies of Bicyclic 2-Pyridone-Containing Peptidomimetics

  摘要：

  The structure-based design, chemical synthesis. and biological evaluation of bicyclic 2-pyridone-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. An optimized compound is shown to exhibit antiviral activity when tested against a variety of HRV serotypes (EC50's ranging from 0.037 to 0.162 muM). (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00008-2

文献信息

• Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
  申请人：——

  公开号：US20010047006A1

  公开（公告）日：2001-11-29

  Compounds of the formula: 1 where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the picornaviral 3C protease. Also disclosed are compounds of the formula: 2 where the formula variables are as defined herein that advantageously inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as rhinovirus 3C proteases. Intermediates and synthetic methods for preparing such compounds are also described.

  披露了具有以下公式的化合物： 1 其中公式变量如本文所述定义，这些化合物能够有优势地抑制或阻断小RNA病毒3C蛋白酶的生物学活性。还披露了具有以下公式的化合物： 2 其中公式变量如本文所述定义，这些化合物能够有优势地抑制或阻断小RNA病毒3C蛋白酶的生物学活性。这些化合物以及含有这些化合物的药物组合物对于治疗感染了一种或多种小RNA病毒的患者或宿主是有用的，例如鼻病毒3C蛋白酶。还描述了用于制备这些化合物的中间体和合成方法。
• [EN] ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS<br/>[FR] COMPOSES ET COMPOSITIONS ANTI-PICORNAVIRUS; UTILISATIONS PHARMACEUTIQUES ET MATERIAUX EMPLOYES POUR LEUR SYNTHESE
  申请人：AGOURON PHARMA

  公开号：WO2001040189A1

  公开（公告）日：2001-06-07

  Compounds of formula (I), where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the picornaviral 3C protease. Also disclosed are compounds of formula (II) where the formula variables are as defined herein that advantageously inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as rhinovirus 3C proteases. Intermediates and synthetic methods for preparing such compounds are also described.

  本发明披露了式(I)的化合物，其中式变量如本文所定义，这些化合物有利地抑制或阻断了小肠病毒3C蛋白酶的生物活性。本发明还披露了式(II)的化合物，其中式变量如本文所定义，这些化合物有利地抑制或阻断了小肠病毒3C蛋白酶的生物活性。这些化合物以及含有这些化合物的药物组合物，对于治疗感染一种或多种小肠病毒（如鼻病毒3C蛋白酶）的患者或宿主非常有用。还描述了制备这些化合物的中间体和合成方法。
• ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS
  申请人：AGOURON PHARMACEUTICALS, INC.

  公开号：EP1252145A1

  公开（公告）日：2002-10-30
• US6514997B2
  申请人：——

  公开号：US6514997B2

  公开（公告）日：2003-02-04
• Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. Part 7: Structure–Activity Studies of Bicyclic 2-Pyridone-Containing Peptidomimetics
  作者：Peter S. Dragovich、Thomas J. Prins、Ru Zhou、Theodore O. Johnson、Edward L. Brown、Fausto C. Maldonado、Shella A. Fuhrman、Leora S. Zalman、Amy K. Patick、David A. Matthews、Xinjun Hou、James W. Meador、Rose Ann Ferre、Stephen T. Worland

  DOI：10.1016/s0960-894x(02)00008-2

  日期：2002.3

  The structure-based design, chemical synthesis. and biological evaluation of bicyclic 2-pyridone-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. An optimized compound is shown to exhibit antiviral activity when tested against a variety of HRV serotypes (EC50's ranging from 0.037 to 0.162 muM). (C) 2002 Elsevier Science Ltd. All rights reserved.